Inhaled corticosteroids downregulate SARS-CoV-2-related genes in COPD: results from a randomised controlled trial

This article has been Reviewed by the following groups

Read the full article See related articles

Abstract

No abstract available

Article activity feed

  1. SciScore for 10.1101/2020.08.19.20178368: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    Institutional Review Board Statementnot detected.
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.
    Sex as a biological variablenot detected.

    Table 2: Resources

    No key resources detected.


    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


    Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
    There are several limitations to our study. First, the relatively small sample size may explain why there were many non-significant trends in pre- to post-treatment change in gene expression. However, the largely consistent directions of change between ICS treatment arms suggests these effects were not due to chance alone. Second, we do not have longer-term follow-up gene expression data to know if the observed changes are durable. Third, we enrolled only stable participants so cannot know if ICS alters the expression of these genes during unstable periods. Fourth, we studied gene rather than protein expression and so cannot necessarily infer changes in protein levels or function. Finally, our data were derived from BECs rather than alveolar or endothelial cells, and may not directly reflect the risk of SARS-CoV-2 infection or ALI in the lung. Our results show that ICS medications have activity on the expression of key SARSCoV-2 related genes in COPD patients, and that expression of the SARS-CoV-2 receptor gene ACE2 is closely related to the expression of anti-viral IFN-I pathways. Whether this translates into altered COVID-19 outcomes requires further study: there are at least two RCTs currently underway (http://clinicaltrials.gov identifiers NCT04381364 and NCT04355637) which may shed some light. Ultimately, optimal control of COPD symptoms and exacerbation risk may be the most important determinants of clinical outcomes in these patients. For this reason, we agree with the...

    Results from TrialIdentifier: We found the following clinical trial numbers in your paper:

    IdentifierStatusTitle
    NCT02833480RecruitingA Study to Investigate the Differential Effects of Inhaled S…
    NCT04381364RecruitingInhalation of Ciclesonide for Patients With COVID-19: A Rand…
    NCT04355637RecruitingInhaled Corticosteroid Treatment of COVID19 Patients With Pn…


    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


    Results from JetFighter: We did not find any issues relating to colormaps.


    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.